ALMS
AlumisยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ALMS Profile
Alumis Inc.
A clinical-stage biopharmaceutical company focused on developing oral therapeutics for the treatment of immune-mediated diseases
280 East Grand Avenue South San Francisco, California 94080
--
Alumis Inc., a Delaware corporation, was incorporated on January 29, 2021. They are a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor they are developing to achieve maximum targeted inhibition, and A-005, a central nervous system osmotic molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapy.
